{
    "2020-06-21": [
        [
            {
                "time": "",
                "original_text": "【民生医药|周报】医药牛市思考，选赛道vs选标的",
                "features": {
                    "keywords": [
                        "医药",
                        "牛市",
                        "赛道",
                        "标的"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "阳勇: 用钻石的标准高品质选股 看好医药行业12个方向",
                "features": {
                    "keywords": [
                        "钻石标准",
                        "高品质",
                        "选股",
                        "医药行业",
                        "方向"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【药咖君】2款全球TOP10畅销药“危”；默沙东PD-1“双喜”；$89.8亿临床急需药上市、恒瑞1类新药",
                "features": {
                    "keywords": [
                        "全球TOP10",
                        "畅销药",
                        "默沙东",
                        "PD-1",
                        "临床急需药",
                        "恒瑞",
                        "新药"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "疫情常态化下，医药投资的变与不变",
                "features": {
                    "keywords": [
                        "疫情",
                        "常态化",
                        "医药投资",
                        "变化",
                        "不变"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}